半胱氨酸组织蛋白酶与动脉粥样硬化心血管疾病的关系
|
摘要
<正>动脉粥样硬化性心血管疾病(ASCVD)是一种以广泛的动脉壁基质蛋白降解为特征的炎症性疾病,持续的炎症和重塑过程将最终破坏动脉壁。来自人类组织和临床前动物模型已经明确了半胱氨酸组织蛋白酶在细胞外基质(ECM)的重塑与动脉粥样硬化性心血管病变的发展密切相关。本文综述了近年来这一领域的研究进展,着重介绍
引文
[1]Weiss-Sadan T,Gotsman I,Blum G.Cysteine proteases in atherosclerosis[J].The FEBS Journal,2017.
[2]Sena BF,Luiz FJ,Elena A.Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease[J].Frontiers in Cardiovascular Medicine,2018,4:88.
[3]Memmert S,Nokhbehsaim M,Damanaki A,et al.Role of cathepsin S In periodontal wound healing-an in vitro study on human PDL cells[J].BMC Oral Health,2018,18(1):60.
[4]Li X,Liu Z,Cheng Z,et al.Cysteinyl Cathepsins:Multifunctional Enzymes in Cardiovascular Disease[J].Chonnam Medical Journal,2012,48(2):77-85.
[5]Wu H,Du Q,Dai Q,et al.Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases:[J].Journal of Atherosclerosis&Thrombosis,2018,25(2):111-23.
[6]Qin Y,Shi GP.Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases[J].Pharmacology&Therapeutics,2011,131(3):338-50.
[7]Pandey G,Bakhshi S,Thakur B,et al.Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia[J].Leukemia&Lymphoma.
[8]Guay D,Beaulieu C,David Percival M.Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors[J].Current Topics in Medicinal Chemistry,2010,10(7):708-16.
[9]Khaket TP,Singh MP,Khan I,et al.Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells[J].Cellular Signalling,2018:S0898656818300640.
[10]Liu CL,Guo J,Zhang X,et al.Cysteine protease cathepsins in cardiovascular disease:from basic research to clinical trials[J].Nature Reviews Cardiology,2018.
[11]Wang Y,Jia L,Shen J,et al.Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis[J].PLoS Pathogens,2018,14(1):e1006872.
[12]Guay D,Beaulieu C,David Percival M.Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors[J].Current Topics in Medicinal Chemistry,2010,10(7):708-16.
[13]Hook V,Funkelstein L,Wegrzyn J,et al.Cysteine Cathepsins in the secretory vesicle produce active peptides:Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer\"s disease[J].BBA-Proteins and Proteomics,2012,1824(1):1-104.
[14]Cheng XW,Huang Z,Kuzuya M,et al.Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications[J].Hypertension,2011,58(6):978.
[15]Mark F,Anna-Karin T,Philip G,et al.Cathepsin C inhibitors:property optimization and identification of a clinical candidate[J].Journal of Medicinal Chemistry,2014,57(6):2357-67.
[2]Sena BF,Luiz FJ,Elena A.Cathepsin S As an Inhibitor of Cardiovascular Inflammation and Calcification in Chronic Kidney Disease[J].Frontiers in Cardiovascular Medicine,2018,4:88.
[3]Memmert S,Nokhbehsaim M,Damanaki A,et al.Role of cathepsin S In periodontal wound healing-an in vitro study on human PDL cells[J].BMC Oral Health,2018,18(1):60.
[4]Li X,Liu Z,Cheng Z,et al.Cysteinyl Cathepsins:Multifunctional Enzymes in Cardiovascular Disease[J].Chonnam Medical Journal,2012,48(2):77-85.
[5]Wu H,Du Q,Dai Q,et al.Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases:[J].Journal of Atherosclerosis&Thrombosis,2018,25(2):111-23.
[6]Qin Y,Shi GP.Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases[J].Pharmacology&Therapeutics,2011,131(3):338-50.
[7]Pandey G,Bakhshi S,Thakur B,et al.Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia[J].Leukemia&Lymphoma.
[8]Guay D,Beaulieu C,David Percival M.Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors[J].Current Topics in Medicinal Chemistry,2010,10(7):708-16.
[9]Khaket TP,Singh MP,Khan I,et al.Targeting of cathepsin C induces autophagic dysregulation that directs ER stress mediated cellular cytotoxicity in colorectal cancer cells[J].Cellular Signalling,2018:S0898656818300640.
[10]Liu CL,Guo J,Zhang X,et al.Cysteine protease cathepsins in cardiovascular disease:from basic research to clinical trials[J].Nature Reviews Cardiology,2018.
[11]Wang Y,Jia L,Shen J,et al.Cathepsin B aggravates coxsackievirus B3-induced myocarditis through activating the inflammasome and promoting pyroptosis[J].PLoS Pathogens,2018,14(1):e1006872.
[12]Guay D,Beaulieu C,David Percival M.Therapeutic Utility and Medicinal Chemistry of Cathepsin C Inhibitors[J].Current Topics in Medicinal Chemistry,2010,10(7):708-16.
[13]Hook V,Funkelstein L,Wegrzyn J,et al.Cysteine Cathepsins in the secretory vesicle produce active peptides:Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer\"s disease[J].BBA-Proteins and Proteomics,2012,1824(1):1-104.
[14]Cheng XW,Huang Z,Kuzuya M,et al.Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications[J].Hypertension,2011,58(6):978.
[15]Mark F,Anna-Karin T,Philip G,et al.Cathepsin C inhibitors:property optimization and identification of a clinical candidate[J].Journal of Medicinal Chemistry,2014,57(6):2357-67.